Demars Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Demars Financial Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$404K	Sell	2,554 -50	-2%	-$6.76K	0.11%	89
2026 Q1	$333K	Sell	2,604 -209	-7%	-$26.1K	0.11%	83
2025 Q4	$343K	Hold	2,813	–	–	0.11%	73
2025 Q3	$282K	Sell	2,813 -162	-5%	-$14.6K	0.1%	77
2025 Q2	$247K	Sell	2,975 -35,414	-92%	-$2.83M	0.09%	77
2025 Q1	$3.11M	Buy	38,389 +3,829	+11%	+$342K	1.32%	15
2024 Q4	$3.11M	Buy	+34,560	New	+$3.35M	1.36%	16

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Demars Financial Group's XBI Position: Q2 2026 in Review

Demars Financial Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.9% in Q2 2026, selling an estimated $6.76K and leaving 2,554 shares worth $404K. The position accounts for 0.11% of the portfolio, ranked #89.

Demars Financial Group first reported a position in XBI in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.11M in Q1 2025. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Demars Financial Group held 2,554 shares of State Street SPDR S&P Biotech ETF worth $404K as of Q2 2026.
Demars Financial Group sold 50 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $6.76K.
State Street SPDR S&P Biotech ETF made up 0.11% of Demars Financial Group's portfolio in Q2 2026, its #89 holding.
Demars Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 7 quarters since.
Demars Financial Group's State Street SPDR S&P Biotech ETF position peaked at $3.11M in Q1 2025.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Demars Financial Group's 13F filing for Q2 2026, filed 21 Jul 2026.